Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
High-dose osimertinib for CNS progression in EGFR plus non-small cell lung cancer (NSCLC): A multi-institutional experience. Piper-Vallillo, A., Rotow, J. K., Aredo, J., Shaverdashvili, K., Luo, J., Carlisle, J. W., Husain, H., Muzikansky, A., Heist, R., Rangachari, D., Ramalingam, S. S., Wakelee, H. A., Yu, H., Sequist, L., Bauml, J., Neal, J. W., Piotrowska, Z. AMER SOC CLINICAL ONCOLOGY. 2020
View details for Web of Science ID 000560368303485